The draft resolution discusses a voluntary pool that would collect patent rights, regulatory test data and other information that could be shared between countries for developing medical products.
Countries would still have to issue compulsory licenses to obtain lower-cost drugs, STAT reported. Compulsory licenses are given to a company to allow it to copy a patented drug without the consent of the patent holder.
Compulsory licenses have been a source of disagreement between the pharmaceutical industry and low- and middle-income countries, and the U.S. has historically been against the licenses, according to STAT.
Read the full article here.
More articles on pharmacy:
HHS unveils plan to distribute Gilead’s COVID-19 drug
Two-thirds of hospital pharmacies have reduced staff during COVID-19 pandemic, ASHP survey finds
New CMS rule could raise out-of-pocket drug costs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
